Year: 2018
Type: article
Abstract: Prostate cancer (PCa) is heterogeneous, harboring phenotypically diverse cancer cell types. PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition and evolution of the cancer genome and by epigenetic mechanisms that result in subclonal cellular differentiation. The process of tumor cell differentiation is initiated from a population of prostate cancer stem cells (PCSCs) that possess many phenotypic and functional properties of normal stem cells. Since the initial reports on PCSCs in 2005, there has been much effort to elucidate their biological properties, including unique metabolic characteristics. In this Review, we discuss the current methods for PCSC enrichment and analysis, the hallmarks of PCSC metabolism, and the role of PCSCs in tumor progression. Stem Cells 2018;36:1457-1474.
Source: Stem Cells
DOI: 10.1002/stem.2859
Institutions: Innsbruck Medical University, Universität Innsbruck, Tyrolean Cancer Research Institute, Tongji University, Roswell Park Comprehensive Cancer Center, Shanghai East Hospital, German Cancer Research Center, Helmholtz-Zentrum Dresden-Rossendorf, OncoRay, University Hospital Carl Gustav Carus, German Cancer Research Center (DKFZ) Dresden, German Cancer Consortium (DKTK) Dresden, Technische Universität Dresden
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Austrian Science Fund, Ministry of Science and Technology of the People's Republic of China, Deutsches Zentrum für Luft- und Raumfahrt, Oesterreichische Nationalbank, National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G1337400203, Slow-cycling cells, therapy resistance and clinical implications in prostate cancer, G215985982, Non-invasive exosome-based method to predict HNSCC recurrence after radiotherapy, Der Glutamin-Metabolismus als eine potentielle Zielscheibe für die Erhöhung der Radiosensibilität des Prostatakrebses, G3655562096, G4119534169, G4674049849, G4888091432, G5026016880, G5259495271, G5566852224, G5850682332, G594947785, DEVELOPING NOVEL THERAPEUTICS TARGETING UNDIFFERENTIATED AND CASTRATION-RESISTANT PROSTATE CANCER STEM CELLS, Zentrum für Innovationskompetenz - Nachwuchsgruppe: Biomarker für die individualisierte Strahlentherapie, G7476311014, Breast CSC sensitivity to particle beam radiation, G7913288217, Untersuchung der Rolle einer Neuropilin2/CXCR4 Signalachse bei der Knochenmetastasierung des Prostatakarzinoms, G9000042799, G9000142182, Diabetes Research Center, G929230618, NOVEL MECHANISM-BASED PRECLINICAL CRPC MODELING IMPACTS PERSONALIZED TREATMENTS
OpenAlex ID: W2806604034